Evidence-Based Reviews

Treating ‘depression’ in patients with schizophrenia

Current Psychiatry. 2012 August;11(8):35-39

References

1. Möller HJ. Drug treatment of depressive symptoms in schizophrenia. Clin Schizophr Relat Psychoses. 2008;1(4):328-340.

2. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402.

3. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand. 2002;106(2):83-96.

4. Siris SG, Bench C. Depression and schizophrenia. In: Schizophrenia. Hirsch SR Weinberger DR, eds. Malden, MA: Blackwell Publishing Company; 2003:142-167.

5. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20.

6. Rifkin A, Quitkin F, Klein DF. Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry. 1975;32(5):672-674.

7. Van Putten T, May RP. “Akinetic depression” in schizophrenia. Arch Gen Psychiatry. 1978;35(9):1101-1107.

8. Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975;16(1):43-47.

9. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 1992;33(4):221-232.

10. Clarke DM, Kissame DW. Demoralization: its phenomenology and importance. Aust N Z J Psychiatry. 2002;36(6):733-742.

11. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980;137(7):801-805.

12. Rosen JL, Miller TJ, D’Andrea JT, et al. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85(1-3):124-131.

13. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.

14. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546.

15. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998;55(3):250-258.

16. Emsley RA, Buckley P, Jones AM, et al. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17(2):210-215.

17. Mauri MC, Moliterno D, Rossattini M, et al. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophr Res. 2008;99(1-3):7-12.

18. Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000;157(9):1379-1389.

19. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996;153(6):820-822.

20. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry. 1994;51(2):109-115.

21. Bustillo J, Lauriello J, Horan W, et al. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry. 2001;158(2):163-175.

Antidepressants. If depressive symptoms persist after lowering or changing the antipsychotic, consider a trial of an adjunctive antidepressant. Titrate antidepressants to the recommended dose over 1 month, and continue antiparkinsonian medications. See patients frequently, and ensure that they receive psychosocial support.

Clinical Point

If depressive symptoms persist after lowering or changing the antipsychotic, consider a trial of an adjunctive antidepressant

No randomized trials have compared the efficacy of antidepressants for treating patients with schizophrenia; therefore, it is unclear if there is a preferred agent. Newer antidepressants often are used in depressed patients with schizophrenia because they are less likely to cause anticholinergic side effects. However, anticholinergic activity may be desirable, eg, for patients with akinesia. Caution is required when combining a selective serotonin reuptake inhibitor with clozapine because metabolism interactions could lead to toxic clozapine levels in some patients.¹⁹

If your patient’s depressive symptoms improve after adding an antidepressant, continue that agent along with the antipsychotic and any antiparkinsonian medications. Only 1 study has evaluated maintenance adjunctive antidepressant therapy for depressed patients with schizophrenia who initially responded to antidepressants. It found that imipramine appeared to protect patients from depressive relapse, and patients who received maintenance adjunctive imipramine were less likely to experience worsening psychotic symptoms.²⁰

Depressed schizophrenia patients are most likely to improve if they receive optimal psychosocial intervention,²¹ which consists of nonspecific support and, when indicated, psychosocial rehabilitation services. Change, even positive change, can be stressful, and patients with schizophrenia need every advantage they can get to be successful in moving their lives in a positive direction.

Clinical Point

Depressed schizophrenia patients are most likely to improve if they receive optimal psychosocial intervention

Related Resources

Rybakowski JK, Vansteelandt K, Szafranski T, et al. Treatment of depression in first episode of schizophrenia: Results from EUFEST [published online ahead of print May 22, 2012]. Eur Neuropsychopharmacol. doi:10.1016/j.euroneuro.2012.04.001.
Addington D, Addington J. Calgary Depression Scale for Schizophrenia. www.ucalgary.ca/cdss.

Drug Brand Names

Benztropine • Cogentin
Clozapine • Clozaril
Fluphenazine • Permitil, Prolixin
Haloperidol • Haldol
Imipramine • Tofranil
Olanzapine • Zyprexa
Quetiapine • Seroquel
Risperidone • Risperdal

Disclosure

Dr. Siris reports no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.